window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 23, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Delivery

  • Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development

    Rani reports positive Phase 1 data for oral obesity therapy RT-114

    Rani Therapeutics has reported positive initial Phase 1a data for [...]

    July 16, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Healome raises £2M to advance eye-drop technology for ocular surface diseases

    Healome Therapeutics has raised £2 million in seed funding to [...]

    July 8, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Delivery & Formulation

    Vect-Horus and Servier partner on targeted oligonucleotide therapies for rare CNS diseases

    Vect-Horus has entered a research collaboration and exclusive licence option [...]

    July 3, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    Lonza acquires Nona blood-brain barrier technology for CNS therapies

    Lonza has acquired the rights to Nona Biosciences’ transferrin receptor [...]

    July 3, 2026
  • Drug Delivery & Formulation

    Lubrizol excipient recognised at CPhI China Pharma Excipients Awards

    Lubrizol’s Apisolex polymer has received a Silver award at the [...]

    June 19, 2026
  • Biotech & Pharma Business,Drug Delivery & Formulation,Drug Discovery & Development

    Symeres expands spray drying capacity at New Jersey site to support poorly soluble small molecules

    Symeres has expanded spray drying capabilities at its Cranbury site [...]

    June 10, 2026
  • Drug Delivery & Formulation,Medical devices,Pharmaceuticals and therapeutics

    Nebu~Flow secures £2M Scottish Enterprise grant for nebuliser technology

    Glasgow medical technology company Nebu~Flow has secured a £2 million [...]

    June 8, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Emalex secures US patent for ecopipam orally disintegrating tablet in Tourette syndrome

    Emalex Biosciences has secured a US patent for an orally [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Bio-Sourcing and Tiny Cargo partner to develop oral monoclonal antibodies using milk exosomes

    Bio-Sourcing and Tiny Cargo will develop oral monoclonal antibody therapies [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Therapeutic Areas

    Nanexa targets next-generation ‘fat jab’ with monthly semaglutide delivery platform

    Sweden-based Nanexa has reported preclinical data for a long-acting semaglutide [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Rani reports positive Phase 1 data for oral obesity therapy RT-114
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development
  • Seegene launches global study to evaluate comprehensive PCR testing for respiratory infections
    Categories: Clinical & Regulatory, Digital & Data, Genomics and sequencing, Research & Development
  • Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top